Evidence map›Paper›PMID 19457093›Full record

ArticleJournal of neurochemistry2009

Inhibition of EGF-induced ERK/MAP kinase-mediated astrocyte proliferation by mu opioids: integration of G protein and beta-arrestin 2-dependent pathways.

Mayumi Miyatake, Tal J Rubinstein, Gregory P McLennan, Mariana M Belcheva, Carmine J Coscia

Open access · greenAbstract readComparative Study
In one paragraph

Article in Journal of neurochemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Morphine and gp120 toxic interactions in striatal neurons are dependent on HIV-1 strain.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2012
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mayumi MiyatakeE. A. Doisy Department of Biochemistry and Molecular Biology, St Louis University School of Medicine, Missouri 63104, USA.
Tal J Rubinstein
Gregory P McLennan
Mariana M Belcheva
Carmine J Coscia
Saint Louis University · US

Funding

OPIOID MODULATION OF ASTROCYTE PROLIFERATIONR01DA005412 · NIDA · SAINT LOUIS UNIVERSITY · PI COSCIA, CARMINE JAMES · 1987 to 2008
$2.3M
NIDA NIH HHS DA-05412NIDA NIH HHS R01 DA005412
6 · The paper itself

Abstract

Although micro, kappa, and delta opioids activate extracellular signal-regulated kinase (ERK)/mitogen-activated protein (MAP) kinase, the mechanisms involved in their signaling pathways and the cellular responses that ensue differ. Here we focused on the mechanisms by which micro opioids rapidly (min) activate ERK and their slower (h) actions to inhibit epidermal growth factor (EGF)-induced ERK-mediated astrocyte proliferation. The micro-opioid agonists ([d-ala(2), mephe(4), gly-ol(5)] enkephalin and morphine) promoted the phosphorylation of ERK/MAP kinase within 5 min via G(i/o) protein, calmodulin (CaM), and beta-arrestin2-dependent signaling pathways in immortalized and primary astrocytes. This was based on the attenuation of the micro-opioid activation of ERK by pertussis toxin (PTX), the CaM antagonist, W-7, and siRNA silencing of beta-arrestin2. All three pathways were shown to activate ERK via an EGF receptor transactivation-mediated mechanism. This was disclosed by abolishment of micro-opioid-induced ERK phosphorylation with the EGF receptor-specific tyrosine phosphorylation inhibitor, AG1478, and micro-opioid-induced reduction of EGF receptor tyrosine phosphorylation by PTX, and beta-arrestin2 targeting siRNA in the present studies and formerly by CaM antisense. Long-term (h) treatment of primary astrocytes with [d-ala(2),mephe(4),gly-ol(5)] enkephalin or morphine, attenuated EGF-induced ERK phosphorylation and proliferation (as measured by 5'-bromo-2'-deoxy-uridine labeling). PTX and beta-arrestin2 siRNA but not W-7 reversed the micro-opioid inhibition. Unexpectedly, beta-arrestin-2 siRNA diminished both EGF-induced ERK activation and primary astrocyte proliferation suggesting that this adaptor protein plays a novel role in EGF signaling as well as in the opioid receptor phase of this pathway. The results lend insight into the integration of the different micro-opioid signaling pathways to ERK and their cellular responses.

Indexed as

AnimalsArrestinsAstrocytesbeta-Arrestin 2beta-ArrestinsCell ProliferationCells, CulturedEnkephalin, Ala(2)-MePhe(4)-Gly(5)-Epidermal Growth FactorExtracellular Signal-Regulated MAP KinasesGrowth InhibitorsGTP-Binding ProteinsMAP Kinase Signaling SystemMitogen-Activated Protein KinasesMorphineRatsArrb2 protein, ratArrestinsbeta-Arrestin 2beta-ArrestinsEnkephalin, Ala(2)-MePhe(4)-Gly(5)-Epidermal Growth FactorExtracellular Signal-Regulated MAP KinasesGrowth InhibitorsGTP-Binding ProteinsMitogen-Activated Protein KinasesMorphineReceptors, Opioid, mu

Identifiers

PMID19457093
PMCPMC3236703
OpenAlexW2038603249

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.